Published in J Med Genet on May 11, 2009
Relative role of genetic complement abnormalities in sporadic and familial aHUS and their impact on clinical phenotype. Clin J Am Soc Nephrol (2010) 3.82
Identification of a mutation in complement factor H-related protein 5 in patients of Cypriot origin with glomerulonephritis. Lancet (2010) 3.74
Atypical hemolytic uremic syndrome. Orphanet J Rare Dis (2011) 3.35
Pregnancy-associated hemolytic uremic syndrome revisited in the era of complement gene mutations. J Am Soc Nephrol (2010) 2.51
Successful treatment of DEAP-HUS with eculizumab. Pediatr Nephrol (2013) 2.00
Combined complement gene mutations in atypical hemolytic uremic syndrome influence clinical phenotype. J Am Soc Nephrol (2013) 1.59
Atypical hemolytic uremic syndrome. Semin Nephrol (2013) 1.56
Clinical features of anti-factor H autoantibody-associated hemolytic uremic syndrome. J Am Soc Nephrol (2010) 1.53
Thrombotic microangiopathy and associated renal disorders. Nephrol Dial Transplant (2012) 1.44
New insights into postrenal transplant hemolytic uremic syndrome. Nat Rev Nephrol (2010) 1.36
Recent insights into C3 glomerulopathy. Nephrol Dial Transplant (2013) 1.21
Complement factor H-related protein 1 deficiency and factor H antibodies in pediatric patients with atypical hemolytic uremic syndrome. Clin J Am Soc Nephrol (2012) 1.14
DEAP-HUS: deficiency of CFHR plasma proteins and autoantibody-positive form of hemolytic uremic syndrome. Pediatr Nephrol (2010) 1.05
Factor h: a complement regulator in health and disease, and a mediator of cellular interactions. Biomolecules (2012) 0.99
DGKE and atypical HUS. Nat Genet (2013) 0.98
Hemolytic uremic syndrome: new developments in pathogenesis and treatment. Int J Nephrol (2011) 0.92
Determining the population frequency of the CFHR3/CFHR1 deletion at 1q32. PLoS One (2013) 0.90
Long-term remission of atypical HUS with anti-factor H antibodies after cyclophosphamide pulses. Pediatr Nephrol (2013) 0.90
Severe atypical HUS caused by CFH S1191L--case presentation and review of treatment options. Pediatr Nephrol (2009) 0.88
Factor H autoantibodies and deletion of Complement Factor H-Related protein-1 in rheumatic diseases in comparison to atypical hemolytic uremic syndrome. Arthritis Res Ther (2012) 0.86
Oxidative stress, innate immunity, and age-related macular degeneration. AIMS Mol Sci (2016) 0.83
Novel developments in thrombotic microangiopathies: is there a common link between hemolytic uremic syndrome and thrombotic thrombocytic purpura? Pediatr Nephrol (2011) 0.81
Atypical hemolytic uremic syndrome post-kidney transplantation: two case reports and review of the literature. Front Med (Lausanne) (2014) 0.77
The Genetics of Ultra-Rare Renal Disease. J Pediatr Genet (2016) 0.77
Atypical hemolytic uremic syndrome and mutation analysis of factor H gene in two Tunisian families. Int J Nephrol Renovasc Dis (2010) 0.76
Anti-complement-factor H-associated glomerulopathies. Nat Rev Nephrol (2016) 0.76
Association among Complement Factor H Autoantibodies, Deletions of CFHR, and the Risk of Atypical Hemolytic Uremic Syndrome. Int J Environ Res Public Health (2016) 0.75
A rare case: childhood-onset C3 glomerulonephritis due to homozygous factor H deficiency. CEN Case Rep (2013) 0.75
Excessive activation of the complement system in atypical hemolytic uremic syndrome: is it ready for prime time? Kidney Int (2010) 0.75
Analysis of Linear Antibody Epitopes on Factor H and CFHR1 Using Sera of Patients with Autoimmune Atypical Hemolytic Uremic Syndrome. Front Immunol (2017) 0.75
Clinical Practice Guidelines for the Management of Atypical Hemolytic Uremic Syndrome in Korea. J Korean Med Sci (2016) 0.75
Atypical Hemolytic Uremic Syndrome: A Brief Review. Hematol Rep (2017) 0.75
Positive effects of combined antiretroviral therapy on CD4+ T cell homeostasis and function in advanced HIV disease. Science (1997) 10.35
Terminal complement inhibitor eculizumab in atypical hemolytic-uremic syndrome. N Engl J Med (2013) 7.51
A classification of hemolytic uremic syndrome and thrombotic thrombocytopenic purpura and related disorders. Kidney Int (2006) 2.85
Stimulation of lymphocytes by autologous leukaemic cells in acute leukaemia. Nature (1969) 2.75
A colorimetric in vitro drug sensitivity assay for Plasmodium falciparum based on a highly sensitive double-site lactate dehydrogenase antigen-capture enzyme-linked immunosorbent assay. Am J Trop Med Hyg (2001) 2.73
Complement factor I: a susceptibility gene for atypical haemolytic uraemic syndrome. J Med Genet (2004) 2.55
Cytoplasmic domain heterogeneity and functions of IgG Fc receptors in B lymphocytes. Science (1992) 2.41
The structure of a human type III Fcgamma receptor in complex with Fc. J Biol Chem (2001) 2.33
Interleukin 17, a T-cell-derived cytokine, promotes tumorigenicity of human cervical tumors in nude mice. Cancer Res (1999) 2.23
The same tyrosine-based inhibition motif, in the intracytoplasmic domain of Fc gamma RIIB, regulates negatively BCR-, TCR-, and FcR-dependent cell activation. Immunity (1995) 2.12
Seasonal patterns of bulimia nervosa. Am J Psychiatry (1992) 2.10
Identification of a clone of Escherichia coli O103:H2 as a potential agent of hemolytic-uremic syndrome in France. J Clin Microbiol (1993) 1.94
Cell-mediate cytotoxicity in vitro of human lymphocytes against a tissue culture melanoma cell line (igr3). J Immunol (1975) 1.82
Infusion of Fc gamma fragments for treatment of children with acute immune thrombocytopenic purpura. Lancet (1993) 1.72
Prognostic value of intratumoral interferon gamma messenger RNA expression in invasive cervical carcinomas. J Natl Cancer Inst (1998) 1.71
Regulation of high-affinity IgE receptor-mediated mast cell activation by murine low-affinity IgG receptors. J Clin Invest (1995) 1.70
Rituximab therapy for childhood-onset systemic lupus erythematosus. J Pediatr (2006) 1.70
Initial presentation of childhood-onset systemic lupus erythematosus: a French multicenter study. J Pediatr (2005) 1.66
CD4+Ki67+ lymphocytes in HIV-infected patients are effector T cells accumulated in the G1 phase of the cell cycle. Eur J Immunol (2000) 1.62
Sickness absence at the French National Electric and Gas Company. Br J Ind Med (1987) 1.62
Eculizumab for atypical hemolytic uremic syndrome recurrence in renal transplantation. Am J Transplant (2012) 1.60
Tyrosine-containing motif that transduces cell activation signals also determines internalization and antigen presentation via type III receptors for IgG. Nature (1992) 1.60
Dense deposit disease: a variant of membranoproliferative glomerulonephritis. Kidney Int (1975) 1.59
The development of atypical haemolytic-uraemic syndrome is influenced by susceptibility factors in factor H and membrane cofactor protein: evidence from two independent cohorts. J Med Genet (2005) 1.59
Serum soluble interleukin-2 receptor concentrations as an independent prognostic marker in head and neck cancer. Lancet (2001) 1.58
Angiogenesis and immunity: a bidirectional link potentially relevant for the monitoring of antiangiogenic therapy and the development of novel therapeutic combination with immunotherapy. Cancer Metastasis Rev (2011) 1.55
Identification of constitutional WT1 mutations, in patients with isolated diffuse mesangial sclerosis, and analysis of genotype/phenotype correlations by use of a computerized mutation database. Am J Hum Genet (1998) 1.54
Report on management of renal failure in Europe, XXII, 1991. Nephrol Dial Transplant (1992) 1.53
Characterization and function of T cell Fc gamma receptor. Immunol Rev (1981) 1.50
Differential modulation of stimulatory and inhibitory Fc gamma receptors on human monocytes by Th1 and Th2 cytokines. J Immunol (2001) 1.48
T-cell hybrids bear Fcgamma receptors and secrete suppressor immunoglobulin binding factor. Nature (1979) 1.47
Late vascular complications after bone marrow transplantation for dyskeratosis congenita. Br J Haematol (1991) 1.47
Observational study of the effect of mu-opioid receptor genetic polymorphism on intrathecal opioid labor analgesia and post-cesarean delivery analgesia. Int J Obstet Anesth (2010) 1.47
Scintigraphic screening for renal damage in siblings of children with symptomatic primary vesico-ureteric reflux. BJU Int (2001) 1.46
Safety and long-term efficacy of eculizumab in a renal transplant patient with recurrent atypical hemolytic-uremic syndrome. Am J Transplant (2009) 1.44
Adult biphenotypic acute leukaemia: an entity with poor prognosis which is related to unfavourable cytogenetics and P-glycoprotein over-expression. Br J Haematol (1998) 1.44
Human complement factor H deficiency associated with hemolytic uremic syndrome. J Am Soc Nephrol (1998) 1.43
A new type of acquired C1 inhibitor deficiency associated with systemic lupus erythematosus. Arthritis Rheum (2001) 1.43
Evaluation under field conditions of the colourimetric DELI-microtest for the assessment of Plasmodium falciparum drug resistance. Trans R Soc Trop Med Hyg (2001) 1.42
Cost-effectiveness of the implementation of an enhanced recovery protocol for colorectal surgery. Br J Surg (2013) 1.40
[Apropos of consensus on indications for extrarenal dialysis in chronic renal failure. Interview by M. Herida]. Presse Med (1998) 1.39
Suppression of in vitro antibody synthesis by immunoglobulin-binding factor. J Exp Med (1975) 1.37
Highly resolved chemical imaging of living cells by using synchrotron infrared microspectrometry. Proc Natl Acad Sci U S A (1998) 1.36
Unusual spread of a penicillin-susceptible methicillin-resistant Staphylococcus aureus clone in a geographic area of low incidence. Clin Infect Dis (1999) 1.36
Complement genes strongly predict recurrence and graft outcome in adult renal transplant recipients with atypical hemolytic and uremic syndrome. Am J Transplant (2013) 1.31
Fc epsilon receptor I-associated lyn-dependent phosphorylation of Fc gamma receptor IIB during negative regulation of mast cell activation. J Immunol (1998) 1.28
Absence of allogeneic restriction in human T-cell-mediated cytotoxicity to Epstein-Barr virus-infected target cells. Demonstration of an HLA-linked control at the effector level. J Exp Med (1979) 1.27
Variable expression of CD3-zeta chain in tumor-infiltrating lymphocytes (TIL) derived from renal-cell carcinoma: relationship with TIL phenotype and function. Int J Cancer (1995) 1.25
Role of B cell receptor Ig alpha and Ig beta subunits in MHC class II-restricted antigen presentation. Immunity (1995) 1.25
Abnormal distribution of T cell subsets in athymic mice. J Immunol (1986) 1.22
Successful plasma therapy in hemolytic uremic syndrome with factor H deficiency. Pediatr Nephrol (2001) 1.20
Role of associated gamma-chain in tyrosine kinase activation via murine Fc gamma RIII. EMBO J (1992) 1.20
Isotype regulation of antibody production: T-cell hybrids can be selectively induced to produce IgG1 and IgG2 subclass-specific suppressive immunoglobulin-binding factors. Proc Natl Acad Sci U S A (1983) 1.19
Population pharmacokinetics and pharmacogenetics of tacrolimus in de novo pediatric kidney transplant recipients. Clin Pharmacol Ther (2009) 1.17
Complement mutation-associated de novo thrombotic microangiopathy following kidney transplantation. Am J Transplant (2008) 1.17
The nephropathy associated with male pseudohermaphroditism and Wilms' tumor (Drash syndrome): a distinctive glomerular lesion--report of 10 cases. Clin Nephrol (1985) 1.16
Proliferation of early human myeloid precursors induced by interleukin-1 and recombinant soluble CD23. Blood (1990) 1.15
Hemolytic-uremic syndrome: an analysis of the natural history and prognostic features. Acta Paediatr Scand (1984) 1.15
Suppression of mitogen-induced peripheral B cell differentiation by soluble Fc gamma receptors released from lymphocytes. Eur J Immunol (1980) 1.14
Transcriptional and post-transcriptional alterations of IkappaBalpha in active minimal-change nephrotic syndrome. J Am Soc Nephrol (2001) 1.14
Chemical imaging of nucleic acids, proteins and lipids of a single living cell. Application of synchrotron infrared microspectrometry in cell biology. Cell Mol Biol (Noisy-le-grand) (1998) 1.13
Haemolytic uraemic syndrome and Shiga toxin-producing Escherichia coli infection in children in France. The Société de Néphrologie Pédiatrique. Epidemiol Infect (2000) 1.12
Restoration of the immune system with anti-retroviral therapy. Immunol Lett (1999) 1.12
Serum interleukin 6 and C-reactive protein levels correlate with resistance to IL-2 therapy and poor survival in melanoma patients. Br J Cancer (1994) 1.12
Modulation of interleukin-18 expression in human colon carcinoma: consequences for tumor immune surveillance. Int J Cancer (1999) 1.11
Abdominal manifestations in childhood-onset systemic lupus erythematosus. Ann Rheum Dis (2006) 1.11
Clinical and microbiologic features of urethritis in men in Toulouse, France. Sex Transm Dis (1991) 1.11
Eculizumab: safety and efficacy after 17 months of treatment in a renal transplant patient with recurrent atypical hemolytic-uremic syndrome: case report. Transplant Proc (2010) 1.11
The health data base of a nationwide company - its use in epidemiological studies. J Occup Med (1982) 1.11
Macrophage inflammatory protein-1alpha is induced by human immunodeficiency virus infection of monocyte-derived macrophages. Blood (1996) 1.11
Ten candidate ADAMTS13 mutations in six French families with congenital thrombotic thrombocytopenic purpura (Upshaw-Schulman syndrome). J Thromb Haemost (2004) 1.10
T cell hybridomas coexpressing Fc receptors (FcR) for different isotypes. II. IgA-induced formation of suppressive IgA binding factor(s) by a murine T hybridoma bearing Fc gamma R and Fc alpha R. J Immunol (1983) 1.10
Immunoglobulin-binding factor present on and produced by thymus-processed lymphocytes (T cells). Cell Immunol (1974) 1.10
Mother-to-child transmitted WT1 splice-site mutation is responsible for distinct glomerular diseases. J Am Soc Nephrol (1999) 1.10
The role of the Fc receptor (FcR) of thymus-derived lymphocytes. II. Presence of FcR on suppressor cells and direct involvement in suppression. Eur J Immunol (1977) 1.09
A phase II study of the cancer vaccine TG4010 alone and in combination with cytokines in patients with metastatic renal clear-cell carcinoma: clinical and immunological findings. Cancer Immunol Immunother (2010) 1.08
Interferon enhances the expression of Fc gamma receptors. J Immunol (1980) 1.08
Clinical activity and benefit of irinotecan (CPT-11) in patients with colorectal cancer truly resistant to 5-fluorouracil (5-FU). Eur J Cancer (1999) 1.07
The B subunit of Shiga toxin fused to a tumor antigen elicits CTL and targets dendritic cells to allow MHC class I-restricted presentation of peptides derived from exogenous antigens. J Immunol (2000) 1.07
Interleukin-18: biological properties and clinical implications. Eur Cytokine Netw (2000) 1.06
Phenotypic expression of factor H mutations in patients with atypical hemolytic uremic syndrome. Kidney Int (2006) 1.06
Optical and confocal microscopy observations of screw dislocations in smectic-A liquid crystals. Phys Rev E Stat Nonlin Soft Matter Phys (2006) 1.05
Soluble Fcgamma receptor type III (FcgammaRIII, CD16) triggers cell activation through interaction with complement receptors. J Immunol (1996) 1.05
Differential roles of N- and C-terminal immunoreceptor tyrosine-based inhibition motifs during inhibition of cell activation by killer cell inhibitory receptors. J Immunol (1999) 1.05
A phase II study: docetaxel as first-line chemotherapy for advanced pancreatic adenocarcinoma. Eur J Cancer (2000) 1.05
Ion channel blockers inhibit B cell activation at a precise stage of the G1 phase of the cell cycle. Possible involvement of K+ channels. J Immunol (1990) 1.05
Critical analysis of T cell subset and function evaluation in patients with persistent generalized lymphadenopathy in groups at risk for AIDS. Clin Exp Immunol (1984) 1.04
A Th0/Th2-like function of CD4+CD7- T helper cells from normal donors and HIV-infected patients. J Immunol (1995) 1.03
Impaired IgG synthesis in patients with the nephrotic syndrome. Clin Nephrol (1982) 1.02
WT1 splice-site mutations are rarely associated with primary steroid-resistant focal and segmental glomerulosclerosis. Kidney Int (2000) 1.02
Renal transplantation under prophylactic eculizumab in atypical hemolytic uremic syndrome with CFH/CFHR1 hybrid protein. Am J Transplant (2012) 1.01
Human herpes virus-8 and other risk factors for Kaposi's sarcoma in kidney transplant recipients. Groupe Cooperatif de Transplantation d' Ile de France (GCIF). Transplantation (1999) 1.00
Gastrointestinal complications of post-diarrheal hemolytic uremic syndrome. Eur J Pediatr Surg (2007) 1.00
Signal regulatory proteins negatively regulate immunoreceptor-dependent cell activation. J Biol Chem (1999) 1.00